Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition
Year: 2023
Type: supplementary-materials
Abstract: PI3Kβi (rac-KIN-193) treatment induces the interaction of p85 with a panel of proteins in PTENLOF/BRAFMUT melanoma. RVH-421 were treated with DMSO or 1μM PI3Kβi for 2h. Lysates were subjected to immunoprecipitation using an antibody targeting p85. Proteins in the range of 75 to 250 kDa were identified by LC-MS as described. Total spectra counts were used as a measure for protein quantity. The table summarizes the proteins enriched upon PI3Kβi treatment in the p85 precipitate. A spectral count ratio of 4 (log2 (PI3Kβi /DMSO) > 2) was taken as an arbitrary cutoff for significant enrichment.
Authors: Barbara Herkert, Audrey Kauffmann, Sandra Mollé, Christian Schnell, Thomas Ferrat, Hans Voshol, Janina Juengert, Hélène Erasimus, Grégory Marszalek, Malika Kazic-Legueux, Eric Billy, David Ruddy, Mark Stump, Daniel Guthy, Mitko Ristov, Keith Calkins, Sauveur-Michel Maira, William R. Sellers, Francesco Hofmann, Michael N. Hall, Saskia M. Brachmann
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361875006